The Latest Breaking News from WAT

Waters Corporation has outpaced the broader healthcare sector over the past year, and analysts are reasonably bullish about the stock’s prospects.

Waters Corporation has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Despite Waters Corporation’s outperformance relative to the broader market over the past year, Wall Street analysts remain cautious about the stock’s prospects.

Waters Corporation is all set to release its third-quarter earnings next month, and analysts expect a single-digit profit dip.

Waters has underperformed the Nasdaq over the past year, and analysts are cautious about the stock’s prospects.

Waters Corporation has underperformed relative to the S&P 500 Index over the past year, and Wall Street analysts remain cautious about the stock’s prospects.

Waters is set to release its second-quarter earnings later this month, and analysts project a single-digit earnings dip.

The diagnostics and research industry has witnessed significant growth over the past couple years due to the pandemic-driven tailwinds, growing prevalence of chronic diseases, and rising adoption of advanced technologies. Thus, shares of fundamentally-sound companies Agilent Technologies (A), Waters Corp. (WAT), and Laboratory Corporation of America Holdings (LH) could be…

Waters Corp (NYSE:WAT) reported first-quarter FY22 revenue growth of 16% year-on-year in CC to $690.6 million, above the consensus of $632.8 million. Sales into the pharmaceutical market increased 19% in CC, sales into the industrial market increased 17% in CC, and sales into the academic and government markets increased 4% in CC. Recurring…